Eli Lilly and Company said that a Phase 3 study of its-antibody therapy, necitumumab, has met its primary endpoint of overall survival in patients with metastatic squamous non-small cell lung cancer. Necitumumab is designed to block the ligand binding site of the human epidermal growth factor receptor (EGFR).
